Gap in non-oral prescriptions relative to AHS guidelines represents an opportunity to increase awareness of Tonix’s two FDA-approved non-oral treatments...
Global leader in personalized predictive genetics launches testing operations for geneType disease risk assessments at US based, world-leading genetic laboratory,...
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over...
FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented...
—Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC) Severity and Progression, Highlighting...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of...
Phio's Compound RXI-185 is designed to slow progression of UV induced collagen breakdownMarlborough, Massachusetts--(Newsfile Corp. - June 18, 2024) -...
OXFORD, England and CAMBRIDGE, Mass., June 18, 2024 /PRNewswire/ -- SpyBiotech, a biotechnology company with a novel vaccine platform technology...
The solution, which includes the VENTANA DP 200 slide scanner, Roche's digital pathology workflow software and a display, is now...
PITTSBURGH, June 17, 2024 /PRNewswire/ -- eHealth Technologies -- a leading healthcare technology company that provides a patented cutting-edge technology...
TEL AVIV, Israel, June 17, 2024 /PRNewswire/ -- Briya, a leading medical data retrieval network, proudly announces the appointment of...
Celebrating the bold leaders who disrupt markets, revolutionize industries, and transform lives AUSTIN, Texas, June 17, 2024 /PRNewswire/ -- Ernst...
Houston, Texas--(Newsfile Corp. - June 17, 2024) - Cannabis Bioscience International Holdings (OTC PINK: CBIH) has been valued at $2...
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical...
First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the...
A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s...
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months...
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy...
~ Emphasizes Strong Cash Position, No Debt, and A Dedicated Management Team Focused on Delivering Growth and Value to Shareholders...
COLD SPRING HARBOR, N.Y., June 17, 2024 /PRNewswire/ -- Things aren't always as they seem. Take pancreatic cancer, for example. In...